Tailored Cancer Vaccines? NousCom is working on it! By Clara Rodríguez Fernández 1 minutemin September 30, 2016 -Updated: onJune 22, 2022 1 minutemin Share WhatsApp Twitter Linkedin Email Newsletter Signup - Under Article / In Page"*" indicates required fieldsURLThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* We aren’t leaving Switzerland yet! We took a scenic train to Basel in order to meet nousCom, a very young biotech developing cancer vaccines.City: Basel, SwitzerlandFounded: 2015Employees: unknownFinancial Data: €12M raised in series ARiccardo Cortese, CEOMission: NousCom is a Biotech that develops next generation cancer vaccines with patient- and tumor-specific antigens. Their vaccines combine viruses modified to selectively target tumor antigens and adenoviral vectors for the delivery of cancer antigens.Comment: The company is getting ready to compete against the big players in immuno-oncology with an expert team, big investors, brand-new GMP labs and innovative science. We expect hearing about positive results very soon. And we like the strong presence of women in their Senior Management Board!Feature Image Credit: Labiotech Map Explore other topics: ImmunotherapySwitzerlandVaccines ADVERTISEMENT